PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls

PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the last few years, thanks to the outstanding results coming from the PROfound an TRITON2 studies. Following that, PARPi gained approval also in metastatic, castration-resistant prostate cancer (mCRPC) with mutations...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Franza, M. Claps, G. Procopio
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4b9b8948a268496481a7274502e56def
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b9b8948a268496481a7274502e56def
record_format	dspace
spelling	oai:doaj.org-article:4b9b8948a268496481a7274502e56def2021-11-10T04:22:49ZPARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls1936-523310.1016/j.tranon.2021.101263https://doaj.org/article/4b9b8948a268496481a7274502e56def2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002540https://doaj.org/toc/1936-5233PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the last few years, thanks to the outstanding results coming from the PROfound an TRITON2 studies. Following that, PARPi gained approval also in metastatic, castration-resistant prostate cancer (mCRPC) with mutations in homologous repair (HR) – related genes. Nevertheless, some questions still remain unanswered concerning the management of drug resistance and PARPi-sensitivity in patients harboring alterations in various DNA damage response (DDR) related genes, not only BRCA1 and BRCA2.In this perspective article we focus on the key issues concerning PARPi in mCRPC, specifically those related to drug sensitivity and resistance mechanisms, exploring the possible role of combination therapeutic approaches and trying to depict potential future addresses in translational oncology research.A. FranzaM. ClapsG. ProcopioElsevierarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101263- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 A. Franza M. Claps G. Procopio PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
description	PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the last few years, thanks to the outstanding results coming from the PROfound an TRITON2 studies. Following that, PARPi gained approval also in metastatic, castration-resistant prostate cancer (mCRPC) with mutations in homologous repair (HR) – related genes. Nevertheless, some questions still remain unanswered concerning the management of drug resistance and PARPi-sensitivity in patients harboring alterations in various DNA damage response (DDR) related genes, not only BRCA1 and BRCA2.In this perspective article we focus on the key issues concerning PARPi in mCRPC, specifically those related to drug sensitivity and resistance mechanisms, exploring the possible role of combination therapeutic approaches and trying to depict potential future addresses in translational oncology research.
format	article
author	A. Franza M. Claps G. Procopio
author_facet	A. Franza M. Claps G. Procopio
author_sort	A. Franza
title	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
title_short	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
title_full	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
title_fullStr	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
title_full_unstemmed	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
title_sort	parp inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/4b9b8948a268496481a7274502e56def
work_keys_str_mv	AT afranza parpinhibitorsandmetastaticcastrationresistantprostatecanceruturedirectionsandpitfalls AT mclaps parpinhibitorsandmetastaticcastrationresistantprostatecanceruturedirectionsandpitfalls AT gprocopio parpinhibitorsandmetastaticcastrationresistantprostatecanceruturedirectionsandpitfalls
_version_	1718440644814307328

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls

Ejemplares similares